Clene reports Q3 net loss $11.0M; ALS survival benefit >90% and MS trial meet endpoints

Clene Inc.

2022-Q3 EPS reported -$0.46 revenue$239,000

Net loss of $11.0M ($0.17/share) vs net income $28.9M in Q3 2021; R&D $6.4M, G&A $3.6M.
Cash & securities $16.2M at Sep 30; subsequent $10.8M equity raise and $5.0M loan commitment.
ALS Healey trial: CNM-Au8 30 mg showed >90% reduction in risk of death at 24 weeks (p=0.028-0.075).
VISIONARY-MS Phase 2 met primary LCLA endpoint (p=0.056) and secondary mMSFC (p=0.0207).
Received EU Orphan Drug Designation for CNM-Au8 in ALS; ZnAg COVID trial topline Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clene Inc. reported the quarter ended September 30, 2022 results: net income $11.0 million, EPS $0.17 per share.

Period: the quarter ended September 30, 2022
Net income: $11.0 million
EPS: $0.17 per share
Result: reported results

Exact text from the filing

Clene reported a net loss of $11.0 million, or $0.17 per share, for the quarter ended September 30, 2022, compared to net income of $28.9 million, or $0.47 per basic share and $0.42 per diluted share, for the same period in 2021.

View on SEC.gov

Browse all earnings releases →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-022334

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.